News | August 10, 2025
Divis Laboratories posts consolidated Q1 FY26 PAT of Rs. 545 Cr
Divi's Laboratories has reported total income of Rs. 2,529 crores during the period ended June 30, 2025
Divi's Laboratories has reported total income of Rs. 2,529 crores during the period ended June 30, 2025
Morepen Laboratories has reported total income of Rs. 429.64 crores during the period ended June 30, 2025
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Revenue increased 11.4 per cent to Rs. 8,545 crore
Granules India receives 1 observation from USFDA for Chantilly facility
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The company expects meaningful revenue contribution from this long-term agreement
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
Subscribe To Our Newsletter & Stay Updated
